SION — Sionna Therapeutics, Inc. Stock Price, Chart & AI Report

Positive May 27, 2026 • 12:00 UTC GlobeNewswire Inc. • Na

Sionna Therapeutics to Participate in Upcoming June 2026 Investor Conferences

Sionna Therapeutics, a clinical-stage biopharmaceutical company focused on cystic fibrosis treatment, announced its participation in two major investor conferences in June 2026: the Jefferies Global Healthcare Conference on June 3rd and the Goldman Sachs 47th Annual Global Healthcare Conference on June 10th. The company is developing novel medicines targeting the CFTR protein, with a pipeline of small molecules designed to correct defects caused by the F508del genetic mutation.

SION cystic fibrosis CFTR protein NBD1 stabilizer SION-719 clinical-stage biopharmaceutical investor conference Phase 2a trial

Sentiment note

The company is actively advancing its pipeline with completed enrollment in Phase 2a trials and participating in major investor conferences, demonstrating progress in drug development and investor engagement. The focus on novel CF treatment approaches and the decade of research backing their NBD1 stabilizer technology suggests meaningful scientific advancement.

Positive May 13, 2026 • 12:00 UTC GlobeNewswire Inc. • Na

Sionna Therapeutics to Participate in the 2026 RBC Capital Markets Global Healthcare Conference

Sionna Therapeutics, a clinical-stage biopharmaceutical company focused on cystic fibrosis treatment, announced that management will participate in a fireside chat at the 2026 RBC Capital Markets Global Healthcare Conference on May 20th, 2026. The company is developing novel medicines targeting the CFTR protein, with a focus on NBD1 stabilizers to address the F508del genetic mutation.

SION cystic fibrosis CFTR protein NBD1 stabilizer SION-719 clinical-stage biopharmaceutical F508del mutation Phase 2a trial

Sentiment note

The company has completed enrollment in its Phase 2a proof-of-concept trial (PreciSION CF) for its lead candidate SION-719, demonstrating progress in clinical development. Participation in a major healthcare conference indicates investor confidence and advancement in their pipeline for treating cystic fibrosis.

Positive Apr 27, 2026 • 19:29 UTC The Motley Fool • Jonathan Ponciano

Sionna Insider Sells $2.5 Million in Stock Amid 215% Surge, but Here's What Investors Should Watch

A director of Sionna Therapeutics sold $2.5 million in shares (55,345 shares at $44.67 each) through OrbiMed Private Investments VIII, LP on April 17-18, 2026. Despite the 215% one-year stock surge, the sale represents only 2% of the related party's indirect holdings and reflects normal portfolio trimming. The biotech company is positioned well financially with $310 million in cash and runway into 2028, with Phase 2a data for its lead cystic fibrosis candidate expected this summer.

SION insider sale biotech cystic fibrosis CFTR modulation clinical-stage company Phase 2a data stock performance

Sentiment note

Despite the insider sale, the article presents a positive outlook. The company has strong financial position ($310 million cash, runway to 2028), differentiated CFTR-targeting approach, impressive 215% one-year stock performance, and upcoming catalyst-heavy period with Phase 2a data expected in summer. The insider sale is characterized as routine portfolio trimming rather than a negative signal, and the company's strategic positioning in the cystic fibrosis treatment landscape is highlighted as a potential leadership opportunity.

Neutral Mar 31, 2026 • 01:08 UTC The Motley Fool • Seena Hassouna

Sionna Chief Legal Officer Cashed Out Her Shares. Her Options Are Another Story

Sionna Therapeutics' Chief Legal Officer Jennifer Fitzpatrick exercised and immediately sold 10,250 shares on March 5, 2026, generating approximately $347,000 in proceeds. The sale represented 100% of her direct common stock holdings, though she retains 50,935 options. The transaction was pre-scheduled under a 10b5-1 plan adopted in June 2025, suggesting a planned move rather than a reactive decision. Sionna has two clinical trials with topline data expected mid-2026 and maintains $310.3 million in cash runway through 2028.

SION insider sale stock options biotech cystic fibrosis clinical trials SEC filing executive compensation

Sentiment note

The insider sale is pre-planned and structured (10b5-1 plan), not indicative of loss of confidence. The CLO retains significant option holdings (50,935 options) tied to future clinical data. The company has strong cash runway ($310.3 million through 2028) and two trials with near-term catalysts (mid-2026 data readouts), which are the key value drivers for this clinical-stage biotech.

Neutral Jan 3, 2026 • 19:35 UTC The Motley Fool • Cory Renauer

A Sionna Therapeutics (SION) Insider Sold 33,000 Shares for $1.5 Million

OrbiMed Advisors sold 33,356 shares of Sionna Therapeutics for approximately $1.5 million on December 24, 2025, reducing its indirect holdings to 3.56 million shares. The sale represents a routine disposition as part of structured block sales, not an indication of insider concern. Sionna, a clinical-stage biotech focused on cystic fibrosis treatments, reported positive phase 1 results in June and began phase 2 trials in October, with top-line results expected mid-2026.

SION insider sale cystic fibrosis clinical-stage biotech CFTR protein phase 2 trial OrbiMed Advisors rare disease

Sentiment note

The insider sale is characterized as routine income supplementation rather than a sign of distress, with the seller retaining substantial holdings (3.56M shares). The company shows clinical progress with positive phase 1 results and ongoing phase 2 trials, but remains pre-commercial with significant development risk ahead. The neutral sentiment reflects both positive clinical progress and the inherent uncertainty of clinical-stage biotech development.

Positive Oct 21, 2025 • 11:00 UTC GlobeNewswire Inc. • Sionna Therapeutics

Sionna Therapeutics Announces Initiation of PreciSION CF Phase 2a Trial Evaluating NBD1 Stabilizer, SION-719, When Added to Standard of Care in Participants with Cystic Fibrosis

Sionna Therapeutics initiated a Phase 2a clinical trial evaluating SION-719, a novel NBD1 stabilizer, as an addition to standard cystic fibrosis treatment Trikafta. The trial aims to assess safety, tolerability, and potential improvement in CFTR protein function, with topline data expected in mid-2026.

SION cystic fibrosis clinical trial CFTR protein NBD1 stabilizer Trikafta

Sentiment note

Company is advancing innovative treatment approach, initiating first clinical trial for NBD1 stabilizer, with potential to improve cystic fibrosis treatment outcomes

Positive Aug 27, 2025 • 11:00 UTC GlobeNewswire Inc. • Sionna Therapeutics

Sionna Therapeutics to Participate in Upcoming September Investor Conferences

Sionna Therapeutics, a clinical-stage biopharmaceutical company focused on cystic fibrosis treatments, will participate in two upcoming investor conferences in September 2025, presenting their research on CFTR protein function normalization.

SION cystic fibrosis CFTR protein biopharmaceutical investor conferences

Sentiment note

Company is actively presenting at investor conferences, demonstrating progress in clinical research for cystic fibrosis treatments and potential investor interest

Positive Feb 10, 2025 • 21:03 UTC Benzinga • Globe Newswire

Sionna Therapeutics Announces Closing of $219.2 million Upsized Initial Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares

Sionna Therapeutics, a clinical-stage biopharmaceutical company, announced the closing of its upsized initial public offering, raising $219.2 million. The company is developing novel medicines to treat cystic fibrosis by normalizing the function of the CFTR protein.

SION Sionna Therapeutics IPO cystic fibrosis CFTR protein

Sentiment note

The company successfully completed an upsized IPO, raising a significant amount of capital to fund its development of novel cystic fibrosis treatments, which indicates a positive outlook for the company's future prospects.